J&J claims a Tecvayli/Darzalex combo win
The company has seen a PFS and OS benefit in the phase 3 Majestec-3 trial.
The company has seen a PFS and OS benefit in the phase 3 Majestec-3 trial.
The company will be the first to take a FcRH5-targeting project into phase 3.
Qilu moves its GPRC5D T-cell engager into phase 3, but trispecifics set the new pace.
Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.